Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.

Animal models are powerful tools to analyze the mechanism of the induction of human breast cancer. Here we report a detailed analysis of mammary tumor progression in one mouse model of breast cancer caused by expression of the polyoma middle T oncoprotein (PyMT) in the mammary epithelium, and its comparison to human breast tumors. In PyMT mice, four distinctly identifiable stages of tumor progression from premalignant to malignant stages occur in a single primary tumor focus and this malignant transition is followed by a high frequency of distant metastasis. These stages are comparable to human breast diseases classified as benign or in situ proliferative lesions to invasive carcinomas. In addition to the morphological similarities with human breast cancer, the expression of biomarkers in PyMT-induced tumors is also consistent with those associated with poor outcome in humans. These include a loss of estrogen and progesterone receptors as well as integrin-beta1 expression and the persistent expression of ErbB2/Neu and cyclinD1 in PyMT-induced tumors as they progress to the malignant stage. An increased leukocytic infiltration was also closely associated with the malignant transition. This study demonstrates that the PyMT mouse model is an excellent one to understand the biology of tumor progression in humans.

[1]  Thomas Ried,et al.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.

[2]  D. Talmage,et al.  Variations in polyoma virus genotype in relation to tumor induction in mice. Characterization of wild type strains with widely differing tumor profiles. , 1987, The American journal of pathology.

[3]  W. Muller,et al.  Signal transduction in mammary tumorigenesis: a transgenic perspective , 2000, Oncogene.

[4]  A. Harris,et al.  Tumor-Associated Macrophages in Breast Cancer , 2002, Journal of Mammary Gland Biology and Neoplasia.

[5]  M. Campiglio,et al.  Role of HER2 gene overexpression in breast carcinoma , 2000, Journal of cellular physiology.

[6]  J. Pollard,et al.  Postnatal mammary gland development requires macrophages and eosinophils. , 2000, Development.

[7]  B. Kacinski,et al.  The role of CSF-1 in normal and neoplastic breast physiology. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[8]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[9]  Mina J Bissell,et al.  The organizing principle: microenvironmental influences in the normal and malignant breast. , 2002, Differentiation; research in biological diversity.

[10]  T. Jacks,et al.  Insights into cancer from transgenic mouse models , 1999, The Journal of pathology.

[11]  H. Varmus,et al.  Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice , 1988, Cell.

[12]  J. A. Hamilton,et al.  Expression and amplification of cyclin genes in human breast cancer. , 1993, Oncogene.

[13]  R. Palmiter,et al.  Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. , 1995, Cancer research.

[14]  R. Dickson,et al.  Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models , 2000, Oncogene.

[15]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[16]  J. Russo,et al.  Role of Hormones in Mammary Cancer Initiation and Progression , 2004, Journal of Mammary Gland Biology and Neoplasia.

[17]  S. Lakhani.  The transition from hyperplasia to invasive carcinoma of the breast , 1999, The Journal of pathology.

[18]  S. Nass,et al.  The Loss of Estrogen and Progesterone Receptor Gene Expression in Human Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.

[19]  J. Pollard,et al.  Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development , 2002, Breast Cancer Research.

[20]  B. Hogan,et al.  Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice , 1990, Cell.

[21]  R. Cardiff,et al.  Mammary Disease Mice Model Premalignant Polyoma Middle-T Transgenic Updated Version , 2001 .

[22]  I. Bièche,et al.  Genetic alterations in breast cancer , 1995, Genes, chromosomes & cancer.

[23]  M. Neville,et al.  Hormonal Regulation of Mammary Differentiation and Milk Secretion , 2004, Journal of Mammary Gland Biology and Neoplasia.

[24]  S. Anderson,et al.  An Atlas of Mouse Mammary Gland Development , 2004, Journal of Mammary Gland Biology and Neoplasia.

[25]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[26]  B. Groner,et al.  Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[29]  Andrew V. Nguyen,et al.  Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.

[30]  H. Varmus,et al.  Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer , 2000, Oncogene.

[31]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[32]  G. Merlino.  Regulatory imbalances in cell proliferation and cell death during oncogenesis in transgenic mice. , 1994, Seminars in cancer biology.

[33]  J. Pollard,et al.  Progesterone Inhibits Estrogen-Induced Cyclin D1 and cdk4 Nuclear Translocation, Cyclin E- and Cyclin A-cdk2 Kinase Activation, and Cell Proliferation in Uterine Epithelial Cells in Mice , 1999, Molecular and Cellular Biology.

[34]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[35]  Cheryl Jorcyk,et al.  The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.

[36]  O. Brison,et al.  Gene amplification and tumor progression. , 1993, Biochimica et biophysica acta.

[37]  P. Rosen,et al.  Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. , 1978 .

[38]  J. Pollard,et al.  Colony stimulating factor-1 is required to recruit macrophages into the mammary gland to facilitate mammary ductal outgrowth. , 2002, Developmental biology.

[39]  G. Shyamala.  Progesterone Signaling and Mammary Gland Morphogenesis , 1999, Journal of Mammary Gland Biology and Neoplasia.

[40]  B. Gusterson,et al.  The Basic Pathology of Human Breast Cancer , 2000, Journal of Mammary Gland Biology and Neoplasia.

[41]  P. Blackshear.  Genetically Engineered Rodent Models of Mammary Gland Carcinogenesis: An Overview , 2001, Toxicologic pathology.

[42]  B. Asch.  Tumor viruses and endogenous retrotransposons in mammary tumorigenesis , 2005, Journal of mammary gland biology and neoplasia.

[43]  M. Black,et al.  Association of atypical characteristics of benign breast lesions with subsequent risk of breast cancer , 1972, Cancer.

[44]  Furth Pa.  SV40 rodent tumour models as paradigms of human disease: transgenic mouse models. , 1998 .

[45]  M. Bissell,et al.  The dominance of the microenvironment in breast and ovarian cancer. , 2002, Seminars in cancer biology.